Uncategorized
Spark reports $25.6 million net loss in first quarter
Spark Therapeutics reported a net loss applicable to common stockholders of $25.6 million, or $0.95 per basic and diluted share, in the first quarter compared with a net loss of $10.4 million, or $0.58 per basic and diluted share, in the same quarter of 2015, according to a press release.The company reported $1.3 million in revenue associated with its collaboration with Pfizer. A year ago, quarterly revenue was $2.3 million, attributed to the Pfizer collaboration and a nonrefundable payment after holding discussions with a pharmaceutical company about a potential agreement.